Menu
Search
|

Menu

Close
X

Bioverativ Inc BIVV.OQ (NASDAQ Stock Exchange Global Select Market)

103.81 USD
+0.20 (+0.19%)
As of 8:59 PM GMT
chart
Previous Close 103.61
Open 103.51
Volume 268,952
3m Avg Volume 554,451
Today’s High 104.02
Today’s Low 103.51
52 Week High 104.30
52 Week Low 46.80
Shares Outstanding (mil) 108.18
Market Capitalization (mil) 6,375.17
Forward P/E 13.98
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.92 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY17
1,169
FY16
887
FY15
335
EPS (USD)
FY17
2.735
FY16
4.068
FY15
1.140
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
13.98
32.90
Price to Sales (TTM)
vs sector
6.17
5.77
Price to Book (MRQ)
vs sector
9.48
5.41
Price to Cash Flow (TTM)
vs sector
12.90
23.42
Total Debt to Equity (MRQ)
vs sector
7.36
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
58.16
14.43
Return on Equity (TTM)
vs sector
85.60
16.13

EXECUTIVE LEADERSHIP

Brian Posner
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
John Cox
Chief Executive Officer, Director, Since 2016
Salary: $696,750.00
Bonus: $258,706.00
John Greene
Chief Financial Officer, Executive Vice President, Treasurer, Since 2016
Salary: $84,135.00
Bonus: $500,000.00
Rogerio Vivaldi Coelho
Executive Vice President, Chief Global Therapeutic Operations Officer, Since 2016
Salary: $96,154.00
Bonus: $500,000.00
Lucia Celona
Executive Vice President, Chief Human Resources and Corporate Communications Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

225 2nd Ave
WALTHAM   MA   02451-1122

Phone: +1781.6634400

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

SPONSORED STORIES